Home » Stocks » ALKS

Alkermes PLC (ALKS)

Stock Price: $24.48 USD 0.33 (1.37%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 3.93B
Revenue (ttm) 1.04B
Net Income (ttm) -94.63M
Shares Out 160.45M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE 43.67
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $24.48
Previous Close $24.15
Change ($) 0.33
Change (%) 1.37%
Day's Open 24.26
Day's Range 24.08 - 24.53
Day's Volume 653,336
52-Week Range 15.35 - 25.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DUBLIN, July 23, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced the 2021 recipients of grants from the company's signature Alkermes Inspiration Grants® program. Grants were awarded to...

2 days ago - PRNewsWire

DUBLIN, July 21, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

3 days ago - PRNewsWire

As the craze for meme stocks fades away, investors should consider growth investing to generate big returns. Here are 7 growth stocks to buy today.

Other stocks mentioned: ATR, PEXL, RMD, SMP, TPX, VIOG
5 days ago - InvestorPlace

DUBLIN, June 30, 2021 /PRNewswire/ --  Alkermes plc  (Nasdaq: ALKS) today announced the presentation of new health economics and outcomes research related to healthcare resource use (HRU) among veterans...

3 weeks ago - PRNewsWire

DUBLIN, June 22, 2021 /PRNewswire/ -- Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), today announced former professional baseball player and World Series champion, CC Sabathia, as a spokes...

1 month ago - PRNewsWire

Biogen isn't the only company whose shares should benefit from a breakthrough drug.

Other stocks mentioned: ALPN
1 month ago - The Motley Fool

DUBLIN, June 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investigatio...

1 month ago - PRNewsWire

DUBLIN, June 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference...

1 month ago - PRNewsWire

The FDA approves Alkermes' (ALKS) Lybalvi for the treatment of adults with schizophrenia or bipolar I disorder. Shares up

1 month ago - Zacks Investment Research

The FDA has approved Alkermes plc's (NASDAQ: ALKS) Lybalvi, a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity, ...

1 month ago - Benzinga

DUBLIN, June 1, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI™ (olanzapine and samidorphan) for the treatment of ...

1 month ago - PRNewsWire

DUBLIN, May 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will host a webcast and conference call at 4:00 p.m. ET (9:00 p.m.

1 month ago - PRNewsWire

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

DUBLIN, May 20, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Emily Peterson Alva, to the company's Board of Directors ("Board"). Emily ...

2 months ago - PRNewsWire

Biotech stocks frequently make big moves on a single trial result or FDA ruling. These 8 drugmakers are worth watching amid important events on deck this summer.

Other stocks mentioned: BIIB, BMY, BPMC, MYOV, PRVB, SNY, VRTX
2 months ago - Kiplinger

DUBLIN, May 13, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced that the company will begin accepting applications for its Alkermes Inspiration Grants® program beginning on May 20, 202...

2 months ago - PRNewsWire

An agreement with an activist investor capped a busy month.

2 months ago - The Motley Fool

Keeping track of upcoming events is important.

Other stocks mentioned: HRTX
2 months ago - The Motley Fool

DUBLIN, May 5, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the BofA Securities 2021 Healthcare Conference on Wednesday...

2 months ago - PRNewsWire

DUBLIN, May 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during ...

2 months ago - PRNewsWire

DUBLIN, April 30, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has reached an agreement with Sarissa Capital Management LP ("Sarissa Capital"), a beneficial owner of approxim...

2 months ago - PRNewsWire

Alkermes' (ALKS) earnings rise year over year in the first quarter of 2021. Revenues surpass estimates.

2 months ago - Zacks Investment Research

Alkermes (ALKS) delivered earnings and revenue surprises of 320.00% and 10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 1000.00% year over year to $0.11, which beat the estimate of ($0.02).

2 months ago - Benzinga

DUBLIN, April 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational enginee...

2 months ago - PRNewsWire

DUBLIN, April 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2021. "Our first quarter results reflect solid execution against our strategy...

2 months ago - PRNewsWire

DUBLIN, April 27, 2021 /PRNewswire/ -- Myrelationshipwithalcohol.com, a new website sponsored by Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), goes live today to offer education about alc...

2 months ago - PRNewsWire

Alkermes plc (NASDAQ: ALKS) has initiated a Phase 2 trial, ARTISTRY-6, evaluating nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma who have been previously treated with anti-PD-(L)1 ...

2 months ago - Benzinga

DUBLIN, April 27, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nem...

2 months ago - PRNewsWire

DUBLIN, April 21, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

3 months ago - PRNewsWire

DUBLIN, April 20, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new research from its psychiatry portfolio at the 2021 Congress of the Schizophrenia International ...

3 months ago - PRNewsWire

Alkermes (ALKS) signs a clinical trial collaboration and supply agreement with Merck to evaluate nemvaleukin alfa in combination with Keytruda for treating platinum-resistant ovarian cancer.

Other stocks mentioned: MRK
3 months ago - Zacks Investment Research

DUBLIN, April 7, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. ...

3 months ago - PRNewsWire

DUBLIN, March 25, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at Stifel's 3rd Annual CNS Day on Thursday, Apr. 1, 2021 a...

3 months ago - PRNewsWire

DUBLIN, March 25, 2021 /PRNewswire/ -- Today, Alkermes plc (Nasdaq: ALKS) will host a virtual Investor Day to discuss the company's research and development strategy and portfolio, including updates fro...

4 months ago - PRNewsWire

DUBLIN, March 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), the company's investigational engineered inte...

4 months ago - PRNewsWire

DUBLIN, Feb. 18, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday...

5 months ago - PRNewsWire

Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.

5 months ago - Zacks Investment Research

The biotech posted a big year-over-year sales decline. But there was a good reason for it.

5 months ago - The Motley Fool

Alkermes (ALKS) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

DUBLIN, Feb. 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 11, 2021 to discuss the company's ...

5 months ago - PRNewsWire

DUBLIN, Jan. 6, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 39th Annual J.P. Morg...

6 months ago - PRNewsWire

Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, part...

Other stocks mentioned: BMRN, IONS
6 months ago - Forbes

DUBLIN, Dec. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the company's New Drug Application (NDA) re...

6 months ago - PRNewsWire

Alkermes (ALKS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

7 months ago - Zacks Investment Research

Alkermes' (ALKS) Value Enhancement Plan is set to drive growth, improve operational and financial performance, as well as enhance shareholder value.

7 months ago - Zacks Investment Research

The biotech has a plan to increase profitability.

7 months ago - The Motley Fool

DUBLIN, Dec. 10, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced a Value Enhancement Plan, or the Plan, designed to drive growth, improve operational and financial performance and enhan...

7 months ago - PRNewsWire

Alkermes (ALKS) gets a CRL by the FDA for ALKS 3831 for the treatment of adults with schizophrenia and bipolar I disorder.

8 months ago - Zacks Investment Research

DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Dru...

8 months ago - PRNewsWire

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizop... [Read more...]

Industry
Biotechnology
IPO Date
Jul 16, 1991
Stock Exchange
NASDAQ
Ticker Symbol
ALKS
Full Company Profile

Financial Performance

In 2020, Alkermes's revenue was $1.04 billion, a decrease of -11.29% compared to the previous year's $1.17 billion. Losses were -$110.86 million, -43.62% less than in 2019.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Alkermes stock is "Hold." The 12-month stock price forecast is 22.44, which is a decrease of -8.33% from the latest price.

Price Target
$22.44
(-8.33% downside)
Analyst Consensus: Hold